Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma

@article{Allen2004PhaseIS,
  title={Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma},
  author={S. Allen and L. Schacter and S. Lichtman and R. Bukowski and D. Fusco and M. Hensley and P. O'dwyer and A. Mittelman and B. Rosenbloom and S. Huybensz},
  journal={Investigational New Drugs},
  year={2004},
  volume={14},
  pages={213-217}
}
SummaryPurpose: To determine the response rate of patients withrefractory/relapsed non-Hodgkin's lymphoma to treatment with elsamitrucin and to further characterize the toxic effects of elsamitrucin in this group of patients. Patients and methods: Eligibility required pathologically verified relapsed or refractory non-Hodgkin's lymphoma with no more than two prior chemotherapy regimens for patients with tumors classified by the International Working Formulation (IWF) as A-C and no more than one… Expand
Emerging DNA topoisomerase inhibitors as anticancer drugs
Emerging DNA topisomerase inhibitors as anticancer drugs.
  • W. Denny
  • Biology, Medicine
  • Expert opinion on emerging drugs
  • 2004
Structures and biological activities of novel 4’-acetylated analogs of chrysomycins A and B
DNA Topoisomerases in Cancer Therapy
Selective binding of small molecules to DNA: application and perspectives.

References

SHOWING 1-10 OF 11 REFERENCES
Phase II study of elsamitrucin in non-small cell lung cancer
Phase I trial and clinical pharmacology of elsamitrucin.
Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.
  • J. Verweij, J. Wanders, +7 authors S. Kaye
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 1994
Experimental antitumor activity of BMY-28090, a new antitumor antibiotic
Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
Phase II studies of elsamitrucin in four different tumor
  • types. Ann Oncol 3(suppl
  • 1992
Phase II studies of elsamitrucin in four different tumor types
  • Ann Oncol
  • 1992
Yovan N: Bristol-Myers Squibb Investigator's brochure: Elsamitrucin
  • Bristol-Myers Squibb, Evansville,
  • 1992
HM: Phase I study of elsamicin (BMY-28090)
  • Proc Am Soc Clin Onc 9:71,
  • 1990
Phase I study of elsamicin ( BMY - 28090 )
  • Proc Am Soc Clin Onc
  • 1990
...
1
2
...